Profile data is unavailable for this security.
About the company
Magforce AG is a Germany-based company engaged in the provision of nanotechnology solutions for health sector. Its non-invasive technology uses magnetic nanoparticles to combat tumors, without harmful effect on the healthy tissues. The Company's range of treatment products includes NanoTherm Therapie for treating tumors locally; NanoTherm, a fluid containing ferrous oxide molecules that penetrate deeply into the tumor tissues and reacting to the presence of a magnetic field; NanoActivator, which are iron oxide nanoparticles for tumors in all areas of the body, and NanoPlan, a software platform that facilitates therapy planning and adjusts proper temperatures for the treatment and and the necessary magnetic field strength. As of December 31, 2011, Nanostart AG held a 49.6%-stake in the Company.
- Revenue in EUR (TTM)351.98k
- Net income in EUR-10.57m
- Incorporated2005
- Employees69.00
- LocationMagforce AGMax-Planck-Strasse 3BERLIN 12489GermanyDEU
- Phone+49 303083800
- Fax+49 3 030838099
- Websitehttps://www.magforce.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paion AG | -100.00bn | -100.00bn | 73.01k | 64.00 | -- | -- | -- | -- | -- | -- | -- | -0.4074 | -- | -- | -- | -- | -- | -24.86 | -- | -34.32 | -- | -- | -- | -52.40 | 0.5078 | -- | 1.17 | -- | 366.42 | 41.74 | 97.34 | -- | 129.37 | -- |
| MagForce AG | 351.98k | -10.57m | 119.73k | 69.00 | -- | 0.0045 | -- | 0.3402 | -0.3531 | -0.3531 | 0.0118 | 0.8967 | 0.0055 | 3.47 | 0.8532 | 5,101.16 | -16.47 | -3.78 | -31.53 | -6.78 | -89.95 | 25.30 | -3,004.22 | -295.23 | 0.0321 | -1.97 | 0.2485 | -- | -43.33 | -5.77 | -171.71 | -- | -- | -- |
| Oxurion NV | 3.00k | 119.00k | 333.07k | 11.00 | -- | -- | 1.28 | 111.02 | -1.48 | -1.48 | 0.0014 | -3.46 | 0.0005 | -- | 0.0018 | 272.73 | 1.94 | -101.52 | -- | -249.96 | -1,333.33 | 53.85 | 3,966.67 | -2,672.68 | -- | 1.47 | 42.11 | -- | -98.86 | -76.22 | 100.63 | -- | -- | -- |
| bioXXmed AG | 4.99k | -21.00m | 557.32k | 1.00 | -- | 2.38 | -- | 111.69 | -34.12 | -34.12 | 0.0107 | 0.1722 | 0.0005 | -- | 0.0993 | 4,990.00 | -194.29 | -32.69 | -195.04 | -33.41 | -- | -- | -420,847.50 | -19,770.58 | -- | -0.0444 | 0.00 | -- | 42.27 | -- | -2,424.48 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Ruffer LLPas of 28 Feb 2025 | 112.03k | 0.37% |
